Randomized, double-blind, controlled phase 1 trial of the candidate tuberculosis vaccine ChAdOx1-85A delivered by aerosol versus intramuscular route.

BCG ChAdOx1-85A Intramuscular Tuberculosis Vaccine aerosol mucosal

Journal

The Journal of infection
ISSN: 1532-2742
Titre abrégé: J Infect
Pays: England
ID NLM: 7908424

Informations de publication

Date de publication:
17 Jun 2024
Historique:
received: 27 03 2024
revised: 11 06 2024
accepted: 12 06 2024
medline: 20 6 2024
pubmed: 20 6 2024
entrez: 19 6 2024
Statut: aheadofprint

Résumé

A BCG booster vaccination administered via the respiratory mucosa may establish protective immune responses at the primary site of Mycobacterium tuberculosis infection. The primary objective of this trial was to compare the safety and immunogenicity of inhaled versus intramuscular administered ChAdOx1-85A. We conducted a single-centre, randomized, double-blind, controlled phase 1 study (Swiss National Clinical Trials Portal number SNCTP000002920). After a dose-escalation vaccination in nine BCG-vaccinated healthy adults, a dose of 1×10 Both vaccination routes were well tolerated with no SAEs. Intramuscular ChAdOx1-85A was associated with more local AEs (mostly pain at injection site) than aerosol ChAdOx1-85A. Systemic AEs occurred in all groups, mainly fatigue and headaches, without differences between groups. Respiratory AEs were not different between BCG-vaccinated groups. Aerosol ChAdOx1-85A vaccination induced Ag85A BAL and systemic cellular immune responses with compartmentalization of the immune responses: aerosol ChAdOx1-85A induced stronger BAL cellular responses, particularly IFNγ/IL17+CD4+ T cells; intramuscular ChAdOx1-85A induced stronger systemic cellular and humoral responses. Inhaled ChAdOx1-85A was well-tolerated and induced lung mucosal and systemic Ag85A-specific T cell responses. These data support further evaluation of aerosol ChAdOx1-85A and other viral vectors as a BCG-booster vaccination strategy. European Commission H2020 program (TBVAC2020 project, grant agreement 643381) via the Swiss State Secretariat for Education, Research and Innovation (SERI).

Sections du résumé

BACKGROUND BACKGROUND
A BCG booster vaccination administered via the respiratory mucosa may establish protective immune responses at the primary site of Mycobacterium tuberculosis infection. The primary objective of this trial was to compare the safety and immunogenicity of inhaled versus intramuscular administered ChAdOx1-85A.
METHODS METHODS
We conducted a single-centre, randomized, double-blind, controlled phase 1 study (Swiss National Clinical Trials Portal number SNCTP000002920). After a dose-escalation vaccination in nine BCG-vaccinated healthy adults, a dose of 1×10
FINDINGS RESULTS
Both vaccination routes were well tolerated with no SAEs. Intramuscular ChAdOx1-85A was associated with more local AEs (mostly pain at injection site) than aerosol ChAdOx1-85A. Systemic AEs occurred in all groups, mainly fatigue and headaches, without differences between groups. Respiratory AEs were not different between BCG-vaccinated groups. Aerosol ChAdOx1-85A vaccination induced Ag85A BAL and systemic cellular immune responses with compartmentalization of the immune responses: aerosol ChAdOx1-85A induced stronger BAL cellular responses, particularly IFNγ/IL17+CD4+ T cells; intramuscular ChAdOx1-85A induced stronger systemic cellular and humoral responses.
INTERPRETATION CONCLUSIONS
Inhaled ChAdOx1-85A was well-tolerated and induced lung mucosal and systemic Ag85A-specific T cell responses. These data support further evaluation of aerosol ChAdOx1-85A and other viral vectors as a BCG-booster vaccination strategy.
FUNDING BACKGROUND
European Commission H2020 program (TBVAC2020 project, grant agreement 643381) via the Swiss State Secretariat for Education, Research and Innovation (SERI).

Identifiants

pubmed: 38897242
pii: S0163-4453(24)00139-7
doi: 10.1016/j.jinf.2024.106205
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

106205

Informations de copyright

Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Régine Audran (R)

Department of Medicine, Division of Allergy and Immunology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.

Olfa Karoui (O)

Department of Medicine, Division of Allergy and Immunology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.

Laura Donnet (L)

Clinical Trial Unit, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne, Lausanne, Switzerland.

Vassili Soumas (V)

Clinical Trial Unit, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne, Lausanne, Switzerland.

Fady Fares (F)

Clinical Trial Unit, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne, Lausanne, Switzerland.

Alban Lovis (A)

Department of Medicine, Division of Pneumology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.

Leslie Noirez (L)

Department of Medicine, Division of Pneumology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.

Matthias Cavassini (M)

Department of Medicine, Division of Infectious Disease, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.

Aurélie Fayet-Mello (A)

Clinical Trial Unit, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne, Lausanne, Switzerland.

Iman Satti (I)

The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.

Helen McShane (H)

The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK. Electronic address: helen.mcshane@ndm.ox.ac.uk.

François Spertini (F)

Department of Medicine, Division of Allergy and Immunology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.

Classifications MeSH